YESAccepted93% confidenceGPT-5.5 (OpenAI)
Question
Will this trial show a positive result on progression Free Survival (PFS) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer?
Found
Outcome Date
Reviewed
Summary
VIKTORIA-1 has trial-specific sponsor readouts for both biomarker cohorts. WT PFS endpoints were described as statistically significant and clinically meaningful; MT cohort later achieved its primary PFS endpoint with clinically meaningful improvement.
Sources
Sponsorcelcuity.com
Celcuity Announces Clinically Meaningful Improvement in Both PFS Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial
Sponsor reported the PIK3CA WT cohort met both PFS primary endpoints with statistically significant and clinically meaningful improvements.
Sponsorcelcuity.com
Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in PFS in PIK3CA Mutant Cohort
Sponsor announced positive topline PIK3CA mutant cohort results and said VIKTORIA-1 achieved its primary PFS endpoint with clinically meaningful improvement.